TKPYY - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
27.935
+0.300 (+1.086%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close27.635
Open0.000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.000 - 0.000
52 Week Range
Volume0
Avg. Volume63,254
Market Cap44.541B
Beta0.42
PE Ratio (TTM)30.53
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.80 (2.96%)
Ex-Dividend Date2016-09-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • We are in recovery mode: Takeda CEO
    CNBC Videos3 months ago

    We are in recovery mode: Takeda CEO

    Christophe Weber, CEO of Takeda Pharmaceutical, talks about how innovation and globalization will help the Japanese company grow in the future.

  • Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run
    InvestorPlace3 days ago

    Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run

    The former is used in combination with Roche’s Zelboraf as a treatment for advanced melanoma. Also, EXEL stock holders are looking at first-line approval for Cabometyx for hepatocellular carcinoma (a type of liver cancer) as potential for significant upside. EXEL retains marketing rights for Cabometyx in the U.S. and it has licensed marketing rights to Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) in Japan and France-based Ipsen S A/S ADR (OTCMKTS:IPSEY) outside the U.S. and Japan.

  • Reuters17 days ago

    Takeda moves ahead in Zika race with launch of vaccine trial

    Japan's Takeda Pharmaceutical has moved ahead in the race to develop a vaccine for the mosquito-borne Zika virus, with the start of a clinical trial programme backed by the U.S. government. Its French rival Sanofi had initially been viewed as the large drugmaker best placed to bring the first vaccine to market when Zika erupted as a major public health hazard in Brazil in 2015. Both Takeda and Sanofi have been working on similar vaccines using inactivated or killed whole Zika virus.

  • Market Realist23 days ago

    What Else Could Boost Exelixis’s Future Revenues?

    On October 16, Exelixis and Ipsen announced that Cabometyx (cabozaninib) met its primary endpoint of OS (overall survival) in the phase-3 Celestial trial.

  • Takeda CEO Seeks Deals to Form Identity Beyond Japan Drug Market
    Bloomberg29 days ago

    Takeda CEO Seeks Deals to Form Identity Beyond Japan Drug Market

    Japan’s biggest drugmaker is ready to take on more partnerships and deals -- at the right price -- as it seeks to build an identity beyond the pharmacy shelves of its home market.

  • American City Business Journalslast month

    Roivant subsidiary stacks up positive Phase 3 news

    The company announced that Takeda Pharmaceutical Company has reported positive top-line results from a Phase 3 study of relugolix in Japan for the treatment of pain associated with uterine fibroids. The positive results – along with those from another Phase 3 study by Takeda of relugolix announced last month – are slated to be used in support of Myovant’s new drug application for relugolix in the U.S. Myovant is currently advancing relugolix for the treatment of uterine fibroid-caused pain and bleeding as well as prostate cancer.

  • Reuterslast month

    Takeda takes on Sanofi with new global dengue vaccine data

    Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia. Japan's top drugmaker has become more international under its French CEO Christophe Weber, who took over in 2015. Sanofi's Dengvaxia is the first-ever approved vaccine for dengue, but it is not perfect and did not protect equally against the four different types of the virus in clinical tests.

  • Capital Cubelast month

    ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : November 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2018 By the Numbers : September 20, 2017
    Capital Cube3 months ago

    Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2018 By the Numbers : September 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Takeda Pharmaceutical Co., Ltd. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Takeda Pharmaceutical Co., Ltd. – Pfizer Inc., Amgen Inc., GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Seattle Genetics, Inc., Sanofi Sponsored ADR, Dr. Reddy’s Laboratories Ltd. ... Read more (Read more...)

  • We want to globalize our products and our company, Takeda Pharmaceutical CEO says
    CNBC3 months ago

    We want to globalize our products and our company, Takeda Pharmaceutical CEO says

    Globalization has been key to Takeda Pharmaceutical's strategy to achieving growth, its CEO said.

  • Market Realist4 months ago

    How Celgene’s Pomalyst Is Positioned after 2Q17

    In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.

  • Capital Cube4 months ago

    ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : August 4, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Seattle Genetics (SGEN) Q2 Loss Narrower than Expected
    Zacks5 months ago

    Seattle Genetics (SGEN) Q2 Loss Narrower than Expected

    Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.

  • Reuters5 months ago

    Nikkei falls to more than 1-week lows as cyclical stocks weigh; Toshiba jumps

    Japan's Nikkei share average fell to a more than one-week low on Tuesday morning after cyclical stocks lost ground as a stronger yen hit sentiment, while Toshiba Corp rallied after news a U.S. hedge fund ...

  • Reuters5 months ago

    U.S. court upholds Takeda patent on cancer drug Velcade

    A U.S. appeals court ruled on Monday that a patent on Takeda Pharmaceutical Co Ltd's cancer treatment Velcade is valid, pushing back the date when generic drug makers including Teva Pharmaceutical Industries Ltd and Mylan NV will be allowed to launch lower-cost versions of the drug in the United States. The U.S. Court of Appeals for the Federal Circuit rejected arguments by a dozen generic drug companies that the Velcade patent was obvious and should not have been granted. The ruling, which reversed a lower court, will allow Takeda to sell Velcade exclusively until the patent expires in 2022.

  • Moody's5 months ago

    Takeda Pharmaceutical Company Limited -- Moody's assigns A1 rating to Takeda Pharmaceutical's USD notes

    Rating Action: Moody's assigns A1 rating to Takeda Pharmaceutical's USD notes. Global Credit Research- 13 Jul 2017. USD500 million of new debt rated.

  • Pill-Popping Is a Business Worth Watching for Japan's Drugmakers
    Bloomberg5 months ago

    Pill-Popping Is a Business Worth Watching for Japan's Drugmakers

    To eke out growth in one of the developed world’s most sluggish pharmaceutical markets, Japanese drugmakers are turning to the pill-popping behavior of their customers.

  • Capital Cube5 months ago

    ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : July 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q4, 2017 By the Numbers : July 4, 2017
    Capital Cube5 months ago

    Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q4, 2017 By the Numbers : July 4, 2017

    Categories: Yahoo FinanceGet free summary analysis Takeda Pharmaceutical Co., Ltd. reports financial results for the quarter ended March 31, 2017. Highlights Summary numbers: Revenues of USD 3,664.99 million, Net Earnings of USD -446.75 million. Gross margins widened from 60.15% to 60.38% compared to the same period last year, operating (EBITDA) margins now 8.25% from 8.16%. Change in ... Read more (Read more...)

  • Japan's Cushy Retirement Gigs Face Greater Scrutiny
    Bloomberg6 months ago

    Japan's Cushy Retirement Gigs Face Greater Scrutiny

    For decades, Japanese boards allowed former executives to linger on in highly paid advisory roles, without offering shareholders much detail. Now, there are signs that cushy retirement gigs may no longer ...